Swibrace, a Fribourg-based medtech company specializing in advanced orthopedic solutions, has announced the commencement of the clinical phase for its patented wrist braces designed to treat distal radius, rhizarthrosis, and scaphoid fractures. This milestone follows the successful conclusion of preclinical studies and marks a significant advancement in the treatment of these complex injuries, typically resulting from high-energy impacts like falls or motorcycle accidents.
Founded in 2017 and collaborating closely with institutions such as the Idiap Research Institute in Martigny (canton of Valais), CSEM and HES-SO University of Applied Sciences in Fribourg, Swibrace leverages cutting-edge 3D printing technologies to produce patient-specific orthopedic splints. These splints are tailored to fit the unique anatomical features of each patient, offering a significant improvement over traditional, one-size-fits-all solutions.
Enhanced healing solutions for patients globally
The company’s innovative Patient Support and Brace Systems (PSABs) are not only custom-fitted but also feature breathable and waterproof materials that reduce infection risks and prevent muscle atrophy. This approach promotes a more comfortable and effective healing process, addressing both the physical and lifestyle needs of patients.
Earlier this year, Swibrace initiated a project with the Inselspital in Bern to develop and test these specialized wrist splints. The resulting clinical study, published in the Journal of Wrist Surgery, has validated the effectiveness of these 3D-printed splints in clinical settings. “We are pleased to introduce our 3D-printed wrist splints—a demonstration of Swibrace’s commitment to patient-specific care,” said Professor Frédéric Schuind, CEO and Founder of Swibrace SA. “The study highlights how additive manufacturing can improve the treatment of distal radius, rhizarthrosis, and scaphoid fractures.”
With the transition into the clinical phase, Swibrace is now positioned to commercialize its wrist braces, which are available for direct request at the Inselspital or through the company’s website. Looking ahead, Swibrace is committed to expanding its product range to include treatments for other types of fractures and is actively engaging with potential partners to broaden its market reach.
